


## AMENDMENTS TO THE CLAIMS

1. (Withdrawn) A method of protecting a patient from one or more treatments that trigger apoptosis comprising administering to the patient a composition comprising a pharmaceutically acceptable amount of a PTEN inhibitor selected from the group consisting of compounds I-XIV.
2. (Withdrawn) The method of claims 1, wherein the treatment is a cancer treatment.
3. (Withdrawn) The method of claim 2, wherein the PTEN inhibitor is administered prior to, together with, or after a treatment for the cancer.
4. (Withdrawn) The method of claim 2, wherein the treatment is chemotherapy or radiation therapy.
5. (Currently Amended) A method of treating ~~a patient suffering from~~ damage to normal tissue attributable to heart disease, comprising administering to ~~the a patient in need thereof~~ a composition comprising a pharmaceutically acceptable amount of a PTEN inhibitor having the formula:



wherein,

$R^1$  represents H,  $\text{NO}_2$ ,  $\text{NR}^5\text{R}^6$ , halogen, cyano, alkyl, alkylaryl, carbonyl, carboxy,  $\text{COR}^2$ , or  $\text{CONR}^5\text{R}^6$ ;

$R^2$  and  $R^3$  independently represent H,  $\text{C}^1\text{-C}^4$  alkyl, aryl, or alkylaryl;

$R^4$  represents H,  $\text{C}^1\text{-C}^4$ , alkyl, aryl, alkylaryl,  $\text{SO}_2\text{R}^2$ ,  $\text{NHSO}_2\text{R}^2$ ,  $\text{NHCOR}^2$ ,  $\text{NHCO}_2\text{R}^2$ ,  $\text{N}=\text{CR}^2\text{R}^3$ , or  $\text{NR}^5\text{R}^6$ ;

$R^5$  and  $R^6$  independently represent H,  $\text{C}^1\text{-C}^4$  alkyl, aryl, alkylaryl,  $(\text{CH}_2)_n\text{COXR}^2$ ,  $(\text{CH}_2)_n\text{XR}^2$ ,  $(\text{CH}_2)_n\text{CO}(\text{CH}_2)_m\text{XR}^2$ ,  $\text{SO}_2\text{R}^2$ ,  $(\text{CH}_2)_n\text{CO}(\text{CH}_2)_n\text{COXR}^2$ , or  $(\text{CH}_2)_n\text{XR}^2$ ;

$m=0\text{-}3$ ;

$n=0\text{-}3$ ; and

X represents  $\text{CR}^3\text{R}^3$ , O, or  $\text{NR}^4$ .

6. (Previously Presented) The method of claim 5, wherein the PTEN inhibitor is administered prior to, together with, or after a treatment for a disease suffered by the patient.
7. (Withdrawn) A method of sensitizing cancer cells to an inhibitor of the PI3 kinase pathway comprising administering to a patient in need of such treatment a PTEN inhibitor selected from the group consisting of compounds I-XIV.

8. (Withdrawn) A method of treating apoptosis associated with a medical procedure comprising administering to a patient in need of such treatment a PTEN inhibitor selected from the group consisting of compounds I-XIV.


9. (Withdrawn) A method of protecting a patient from radiation or chemical exposure comprising administering to the patient a composition comprising a pharmaceutically acceptable amount of a PTEN inhibitor selected from the group consisting of compounds I-XIV.

10. (Withdrawn) The method of claim 9 wherein the PTEN inhibitor is administered prior to, together with, or after the said radiation or chemical exposure.

11. (Withdrawn) A method of sensitizing cancer stem cells by exposing said cells to a PTEN inhibitor selected from the group consisting of compounds I-XIV.

12. (Withdrawn) The method of claim 9 wherein the PTEN inhibitor is administered prior to, together with, or after a treatment for a disease suffered by the patient.

13. (New) A method of treating damage to normal tissue attributable to heart disease, comprising administering to a patient in need thereof a composition comprising a pharmaceutically acceptable amount of a PTEN inhibitor having the formula:



14. (New) The method of claim 13, wherein the PTEN inhibitor is administered prior to, together with, or after a treatment for a disease suffered by the patient.